The role of protein p53 in neurodegenerative processes throughout the 25 years of its history;La proteína p53 en procesos neurodegenerativos en sus 25 años de historia

Revista de Neurologia

Volumn 39, Issue 3, 2004, Pages 243-250

  Gomez Lazaro M ^a   Fernandez Gomez F J ^a   Jordán, Joaquín ^a,b  

^a Universidad de Castilla La Mancha   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Apoptosis; Cancer; Cell cycle; Genome; Mitochondria; Neurodegeneration; P53; Transcription factors

Indexed keywords

PROTEIN P53; VIRUS LARGE T ANTIGEN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; HISTORY OF MEDICINE; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION;

EID: 4744372189     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3903.2004355     Document Type: Review

References (126)

1. Chang C, Simmons DT, Martin MA, Mora PT. Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol 1979; 31: 463-71.
2. Kress M, May E, Cassingena R, May P. Simian Virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 serum. J Virol 1979; 31: 472-83.
3. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3.
4. Linzer DIH, Levine AJ. Characterization of a 54 kDa cellular SV40 tumor antigen present in SV40-transformed cells and in unfected embryonal carcinoma cells. Cell 1979; 1: 43-52.
5. Melero JA, Stitt DT, Mangel WF, Carroll RB. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in simian virus 40-infected and transformed cells. J Virol 1979; 93: 466-80.
6. De Leo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci 1979; 76: 2420-4.
7. Rotter V, Witte ON, Coffman R, Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, p50. J Virol 1980; 36: 547-55.
8. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-8.
9. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987; 39: 185-9.
10. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
11. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-6.
12. Martin ACR, Facchiano AM, Cuff AL, Hernández-Boussard T, Olivier M, Hainaut P, et al. Integrating Mutation Data and Structural Analysis of the TP53 Tumor-Supressor Protein. Human Mutation 2002; 19: 149-64.
13. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
14. Yang A, Kaghad M, Wang Y, Gillet E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
15. Irwin MS, Kaelin WG Jr. Role of the newer p53 family proteins in malignancy. Apoptosis 2001; 6: 17-29.
16. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 345-55.
17. Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1: 101-10.
18. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985; 5: 2851-5.
19. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
20. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wlls PG. A teratologic suppressor role for p53-deficient mice. Nat Genet 1995; 10: 181-7.
21. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53 deficient mice. Curr Biol 1995; 8: 937-43.
22. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc A Cytoplasmic Anchor for p53. Cell 2003; 112: 29-40.
23. Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, et al. Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells in cell cycle regulated and determined by the nucleus. Cancer Res 1997; 57: 5217-20.
24. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
25. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934-47.
26. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
27. Ohnishi T, Wang X, Ohnishi K, Matsumoto H, Takahashi A. p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells. J Biol Chem 1996; 271: 14510-3.
28. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci 1996; 93: 2442-7.
29. El-Deiry WS, Kem SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-9.
30. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993; 7: 2565-74.
31. Foord O, Navot N, Rotter V. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Mol Cell Biol 1993; 13: 1378-84.
32. Qian H, Wang T, Naumovski L, López CD, Brachmann RK. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002; 21: 7901-11.
33. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998; 19: 175-8.
34. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4: 1689-94.
35. Lu H, Fisher RP, Bailey P, Levine AJ. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 1997; 17: 5923-34.
36. Milne DM, McKendrick L, Jardine LJ, Deacon E, Lord JM, Meek DW. Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. Oncogene 1996; 13: 205-11.
37. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56: 2649-54.
38. Kubbutat MH, Vousden KH. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 1997; 17: 460-8.
39. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, et al. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 2001; 20: 1630-9.
40. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 1996; 15: 1596-606.
41. Iwakuma T, Lozano G. MDM2, An Introduction. Mol Cancer Res 2003; 1: 993-1000.
42. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999; 96: 3077-80.
43. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53, FEBS Lett 1997; 420: 25-7.
44. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-8.
45. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-4.
46. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 1997; 3: 441-51.
47. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-8.
48. Weber JD, Taylor L, Rousssel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; I: 20-6.
49. Wang X, Taplick J, Geva N, Oren M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett 2004; 561: 195-201.
50. Fiscella M, Ullrich SJ, Zambrano N, Shields MT, Lin D, Lees-Miller SP, et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 1993; 8: 1519-28.
51. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-34.
52. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
53. Gottifredi V, McKinney K, Poyurovsky MV, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem 2004; 279: 5802-10.
54. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochem Biophys Acta 1996; 1287: 77-102.
55. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53.dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404: 42-9.
56. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 2000; 26: 122-7.
57. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
58. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
59. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase. A Mol Cell 1999; 3: 413-22.
60. Dewson G, Cohen GM, Wardlaw AJ. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils. Blood 2001; 98: 2239-47.
61. Jia L, Patwari Y, Srinivasula SM, Newland AC, Fernandes-Alnemri T, Alnemri ES, et al. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 2001; 20: 4817-26.
62. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000; 103: 645-54.
63. Nechushtan A, Smith CL, Lamensdoff I, Yoon SH, Youle RJ. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001; 153: 1265-76.
64. Deng Y, Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci 2000; 97: 12050-5.
65. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area and effect of post mortem delay. J Neurosci 1996; 16: 1710-9.
66. De la Monte SM, Sohn YK, Wands JR. Corretates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997; 152: 73-83.
67. Su JH, Deng GM, Cotman CW. Bax protein expression is increased in Alzheimers brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol. Exp. Neurol 1997; 56: 86-93.
68. Tortosa A, López W, Ferrer I. Bcl-2 and Bax protein expression in Alzheimer's disease. Acta Neuropathol 1998; 95: 407-12.
69. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka ¿¿INICIAL??, Nomura Y, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998; 780: 260-9.
70. Tatton WG, Olanow CW. Apoptosis in neurodegenerative diseases: the role of mithocondria. Biochem Biophys Acta 1999; 1410: 195-214.
71. Burke RE, Kholodilov NG. Programmed cell death: does it playa role in Parkinson's disease? Ann Neurol 1998; 44: 126-33.
72. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Márquez J, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12: 25-31.
73. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150: 119-31.
74. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995; 6: 1053-7.
75. Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998; 87: 49-53.
76. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192: 1-15.
77. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001; 8: 721-38.
78. Li Y, Chopp M, Powers C, Jiang N. Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res 1997; 765: 301-12.
79. Tan Z, Sankar R, Shin D, Sun N, Liu H, Wasterlain CG, et al. Inmunohistochemical study of p53-associated proteins in rat brain following lithium-pilocarpine status epilepticus. Brain Res 2002; 929: 129-38.
80. Raghupathi R, Graham DI, McIntosh TK. Apoptosis after traumatic brain injury. J Neurotrauma 2000; 17: 927-38.
81. Napieralski JA, Raghupathi R, McIntosh TK. The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury. Brain Res Mol Brain Res 1999; 71: 78-86.
82. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 2003; 3: 65-94.
83. Uberti D, Ferrari-Toninelli G, Memo M. Involvement of DNA damage and repair systems in neurodegenerative process. Toxicol Lett 2003; 139: 99-105.
84. Morrison RS, Wenzel HJ, Kinoshita Y, Robbins CA, Donehower LA, Schwartzkroin PA. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci 1996; 16: 1337-45.
85. Uberti D, Belloni M, Grilli M, Spano P, Memo M. Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. Eur J Neurosci 1998; 10: 246-54.
86. Uberti D, Grilli M, Memo M. Contribution of NF-kappaB and p53 in the glutamate-induced apoptosis. Int J Dev Neurosci 2000; 18: 447-54.
87. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-42.
88. Nakai M, Qin ZH, Wang Y, Chase TN. Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. Brain Res Mol Brain Res 1999; 64: 59-68.
89. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994; 5: 2529-33.
90. MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RL, Synek B, et al. Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. Exp Neurol 1997; 147: 316-32.
91. Vélez-Pardo C, Ospina GG, Jiménez-Del Río M. Abeta [25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-kappaB, p53 and c-Jun. Neurotoxicology 2002; 23: 351-65.
92. García-Ospina GP, Jiménez-Del Río M, Lopera F, Vélez-Pardo C. El daño neuronal se correlaciona con la detección in situ de los factores de transcripción c-Jun, factor nuclear kB, p53 y Par-4 y en la entermedad de Alzheimer. Rev Neurol 2003; 36: 1004-10.
93. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817-27.
94. Prehn JH, Bindokas VP, Jordan J, Galindo MF, Ghadge GD, et al. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol 1996; 49: 319-28.
95. Darnton SJ, Jenner K. Microwave irradiation lowers immunohistological detection thresholds for p53 protein in squamous epithelium from non-neoplastic oesophagus. J Pathol 1998; 185: 334-5.
96. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 1994; 81: 1623-6.
97. Girod SC, Groth W, Junk M, Gerlach KL. p53 and PCNA expression in malignant melanomas of the head and neck. Pigment Cell Res 1994; 7: 354-7.
98. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997; 48: 650-8.
99. Lander HM, Ogiste JS, Teng KK, Novogrodsky A, p21ras as a common signaling target of reactive free radicals and cellular redox stress. J Biol Chem 1995; 270: 21195-8.
100. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137-46.
101. Coso OA, Chiariello M, Kalinec G, Kyriakis JM, Woodgett J, Gutkind JS. Transforming G protein-coupled receptors potently activate JNK (SAPK). Evidence for a divergence from the tyrosine kinase signaling pathway. J Biol Chem 1995; 270: 5620-4.
102. Wu H, Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 1994; 9: 20067-74.
103. Mandir AS, Simbulan-Rosenthal CM, Poitras MF, Lumpkin JR, Dawson VL, Smulson ME, et al. A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. J Neurochem 2002; 83: 186-92.
104. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 2002; 21: 990-9.
105. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606.
106. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, et al. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci 2001; 98: 10918-23.
107. Trimmer PA, Smith TS, Jung AB, Bennett JP Jr. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996; 5: 233-9.
108. Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 2002; 32: 1264-75.
109. Da Costa CA, Paitel E, Vincent B, Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J Biol Chem 2002; 277: 50980-4.
110. Da Costa CA, Masliah E, Checler F. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J Biol Chem 2003; 278: 37330-5.
111. Ricaurte GA, Schister CR, Seiden LS. Long-term effects of repeated methylsamphetamine administration on dopamine and serotonin neurons in the rat brain: regional study. Brain Res 1980; 193: 153-63.
112. Hirata H, Cadet JL. P53-knockout mice are protected against the long-term effects of metahamphetamine on dopaminergic terminals and cell bodies. J Neurochem 1997; 69: 780-90.
113. Bakdwin HA, Colado MI, Murry TK, De Souza RJ, Green AR. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol 1993; 108: 590-6.
114. 2 antagonists. J Neurochem 1993; 60: 1792-9.
115. Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 1974; 249: 2447-52.
116. Cadet JL. A unifying hypothesis of movement and madness: involvement of free radicals in disorders of the isodendritic core. Med Hypotheses 1988; 27: 87-94.
117. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 1998; 32: 117-31.
118. Wagner GC, Carelli RM, Jarvis MF. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol Pharmacol 1985; 47: 221-8.
119. Cubells JF, Rayport S, Rajndron G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994; 14: 2260-71.
120. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymetahmphetamine. Brain Res 1992; 581: 237-43.
121. Honma H, Gross L, Windebank AJ. Hypoxia-induced apoptosis of dorsal root ganglion neurons is associated with DNA damage recognition and cell cycle disruption in rats. Neurosci Lett 2004; 354: 95-8.
122. Jordan J, Galindo MF, González-García C, Cena V. Role and regulation of p53 in depolarization-induced neuronal death. Neuroscience 2003; 122: 707-15.
123. Joo CK, Choi JS, Ko HW, Park KY, Sohn S, Chun MH, et al. Necrosis and apoptosis after retinal ischemia: involvement of NMDA-mediated excitotoxicity and p53. Invest Ophthalmol Vis Sci 1999; 40: 713-20.
124. Wosik K, Antel J, Kuhlmann T, Bruck W, Massie B, Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem 2003; 85: 635-44.
125. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis 2000; 7: 613-22.
126. González de Aguilar JL, Gordon JW, Rene F, De Tapia M, Lutz-Bucher B, Gaiddon C, et al. Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis 2000; 7: 406-15.